Pulmonary hypertension: current therapy and future prospects.

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Genetics

Background:

• Pulmonary hypertension (PH) arises from diverse cardiovascular and systemic diseases.
• The most common genetic defect identified in PH is a heterozygous mutation in BMPRII, a TGFβ superfamily member.
• Endothelial dysfunction, characterized by impaired vascular relaxation, increased proliferation, and apoptosis, is central to PH pathogenesis.

Purpose of the Study:

• To review current therapeutic strategies for pulmonary hypertension.
• To explore emerging treatments and future prospects in PH management.
• To highlight the challenges in diagnosing and treating PH due to its insidious nature.

Main Methods:

• Review of current literature on pulmonary hypertension.
• Analysis of existing therapeutic agents and their mechanisms.
• Examination of novel drug candidates and ongoing research, including gene therapy.

Main Results:

• Current therapies primarily target cAMP and cGMP pathways for vascular relaxation and utilize endothelin receptor blockers.
• Emerging treatments like guanylate cyclase activators, PDGF blockers, and RhoA/Rho kinase inhibitors show promise in preclinical and early clinical studies.
• A variety of other pathways (nitrites, PPARγ, ACE2, ghrelin) and gene therapy are under active investigation.

Conclusions:

• Pulmonary hypertension presents diagnostic and therapeutic challenges due to late presentation and varied patient response.
• While current treatments offer some benefit, novel therapeutic approaches are crucial for improving outcomes.
• Continued research into new drugs, signaling pathways, and gene therapy holds significant promise for the future management of PH.